Eusol Bio Business Summary

Eusol Biotech Co., Ltd. (6652.TWO) is a Taiwan-based clinical-stage biopharmaceutical company specializing in the development of therapeutics for neurological disorders and unmet medical needs. The company generates revenue through a hybrid model of proprietary drug development, strategic licensing, and the co-development of niche generics with specialized formulations. Its primary business segments are centered on its lead pipeline assets: ES135, a recombinant human acidic fibroblast growth factor (rhFGF1) targeting spinal cord injury and neural repair, and SM-1, a composite sedative capsule for sleep dysfunction. In a significant strategic shift as of March 2026, the company has transitioned to an outsourced manufacturing model to optimize R&D capital. However, the Taipei Exchange announced the termination of Eusol’s trading on the Emerging Stock Board effective April 10, 2026, following the resignation of its lead advisory firms. Direct competitors include Lukas Biomedical Inc., UnicoCell Biomed Co., Ltd., and Pharmosa Biopharm Inc., with Eusol maintaining a specialized position in the high-barrier neural regeneration and psychiatric medicine markets. The leadership team is anchored by Chairman Dr. Hong-Jen Chang, a prominent figure in Taiwan’s healthcare sector who previously served as the Deputy Minister of Health and the President of the Bureau of National Health Insurance. Dr. Chang, an alumnus of Harvard’s T.H. Chan School of Public Health, brings extensive regulatory and investment pedigree through his concurrent role as Chairman of YFY Biotech Management. The executive management is further supported by CEO Wan-Ya Zhang, who oversees the company’s operational transformation and partnership strategies. Founded in 2005 and headquartered in Taipei, Eusol is backed by notable institutional influence from the YFY Group, leveraging a board with deep expertise in global clinical trials and pharmaceutical commercialization to navigate its late-stage pipeline toward regulatory approval.